Post-transplant diabetes mellitus (PTDM) is a frequent consequence of solid organ
transplantation. PTDM has been associated with greater mortality and increased infections …

The challenges inherent in conducting accurate, clinically effective, and cost-effective
cardiac evaluations among transplantation candidates relate to the large size of the target …

A long-standing association exists between elevated triglyceride levels and cardiovascular
disease*(CVD). 1, 2 However, the extent to which triglycerides directly promote CVD or …

Suppression of allograft rejection is central to successful organ transplantation; thus,
immunosuppressive agents are crucial for successful allograft function. Immunosuppressive …

Mammalian target of rapamycin (mTOR) inhibitors are used as potent immunosuppressive
agents in solid-organ transplant recipients (everolimus and sirolimus) and as antineoplastic …

By the time of renal transplantation, end-stage renal disease patients have a huge burden of
cardiovascular disease (CVD) and are heavily saturated with atherosclerotic risk factors …

Renal transplant recipients have increased mortality rates when compared with the general
population. The new immunosuppressive drugs have improved short-term patient survival …

Successful kidney transplantation offers patients with end-stage renal disease the greatest
likelihood of survival. However, cardiovascular disease poses a major threat to both graft …

Fibrates are an important class of drugs for the management of dyslipidemia. This class of
drugs is generally well tolerated but is infrequently associated with several safety issues …

New onset hyperglycemia and diabetes are associated with increased cardiovascular risk
after kidney transplantation. Background Post-transplant diabetes (PTDM) is a common and …